Marketing of the life sciences: A new framework and research agenda for a nascent field

Journal of Marketing

Volumn 73, Issue 4, 2009, Pages 4-30

  Stremersch, Stefan ^a,b,c   Van Dyck, Walter ^d  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c IESE BUSINESS SCHOOL   (Spain)

^d TILBURG UNIVERSITY   (Netherlands)

Author keywords

Biotechnology; Life sciences; Marketing; Marketing theory; Medical device; Pharmaceutical; Research agenda; Sales

Indexed keywords

EID: 67650109609     PISSN: 00222429     EISSN: None     Source Type: Journal    
DOI: 10.1509/jmkg.73.4.4     Document Type: Article

References (149)

1. Aboulnasr, Khaled, Om Narasimhan, Edward Blair, and Rajesh K. Chandy (2008), "Competitive Response to Radical Product Innovations," Journal of Marketing, 72 (May), 94-110.
2. Agrawal, Nidhi, Geeta Menon, and Jennifer L. Aaker (2007), "Getting Emotional About Health," Journal of Marketing Research, 44 (February), 100-113.
3. Ahearne, Michael, Thomas W. Gruen, and Cheryl Burke Jarvis (1999), "If Looks Could Sell: Moderation and Mediation of the Attractiveness Effect on Salesperson Performance," International Journal of Research in Marketing, 16 (4), 269-84.
4. Ahuja, Gautam (2000), "Collaboration Networks, Structural Holes, and Innovation: A Longitudinal Study," Administrative Science Quarterly, 45 (3), 425-55.
5. Akçura, M. Tolga, Füsun F. Gönül, and Elina Petrova (2004), "Consumer Learning and Brand Valuation: An Application on Over-the-Counter Drugs," Marketing Science, 23 (1), 156-69.
6. Arnold, Matthew (2004), "Directing Compliance," Medical Marketing & Media, 39 (6), 36-46.
7. Azoulay, Pierre (2002), "Do Pharmaceutical Sales Respond to Scientific Evidence?" Journal of Economics and Management Strategy, 11(4), 551-94.
8. Bandura, Albert (1982), "Self-Efficacy Mechanism in Human Agency," American Psychologist, 37 (2), 122-47.
9. Becker, Marshall H. (1974), "The Health Belief Model and Personal Health Behavior," Health Education Monographs, 2 (4), 409-419.
10. -and Irvin M. Rosenstock (1984), "Compliance with Medical Advice," in Health Care and Human Behavior, A. Steptoe and A. Mathews, eds. New York: Academic Press, 175-208.
11. Berger, Jonah A. and Lindsay Rand (2008), "Shifting Signals to Help Health: Using Identity-Signaling to Reduce Risky Health Behaviors," Journal of Consumer Research, 35 (3), 509-518.
12. Berndt, Ernst R., Linda Bui, David R. Reiley, and Glen L. Urban (1995), "Information, Marketing, and Pricing in the U.S. Antiulcer Drug Market," American Economic Review, 85 (2), 100-105.
13. Bhattacharya, Jayanta and William B. Vogt (2003), "A Simple Model of Pharmaceutical Price Dynamics," Journal of Law and Economics, 46 (2), 599-626.
14. Blau, Gary E., Joseph F. Pekny, Vishal A. Varma, and Paul R. Bunch (2004), "Managing a Portfolio of Interdependent New Product Candidates in the Pharmaceutical Industry," Journal of Product Innovation Management, 21 (4), 227-45.
15. Block, Lauren G. and Punam A. Keller (1995), "When to Accentuate the Negative: The Effects of Perceived Efficacy and Message Framing on Intentions to Perform a Health-Related Behavior," Journal of Marketing Research, 32 (May), 192-203.
16. Bolton, Lisa E., Joel B. Cohen, and Paul N. Bloom (2006), "Does Marketing Products as Remedies Create 'Get Out of Jail Free Cards'?" Journal of Consumer Research, 33 (June), 71-81.
17. -, Americus Reed II, Kevin G. Volpp, and Katrina Armstrong (2008), "How Does Drug and Supplement Marketing Affect a Healthy Lifestyle?" Journal of Consumer Research, 34 (5), 713-26.
18. Bourgeois, L.J., III, and Kathleen M. Eisenhardt (1988), "Strategic Decision Processes in High Velocity Environments: Four Cases in the Microcomputer Industry," Management Science, 34 (July), 816-35.
19. Bowman, Douglas, Carrie M. Heilman, and P.B. Seetharaman (2004), "Determinants of Product-Use Compliance Behavior," Journal of Marketing Research, 41 (August), 324-38.
20. Burnett, John J. and Richard L. Oliver (1979), "Fear Appeal Effects in the Field: A Segmentation Approach," Journal of Marketing Research, 16 (May), 181-90.
21. Burns, Lawton R. (2005), The Business of Healthcare Innovation. Cambridge, UK: Cambridge University Press.
22. Camacho, Nuno, Vardit Landsman, and Stefan Stremersch (2009), "The Connected Patient," in The Connected Customer: The Changing Nature of Consumer and Business Markets, Stefan Wuyts, Marnik G. Dekimpe, Els Gijsbrechts, and F.G.M. Pieters, eds. Hampshire, UK: Routledge Academic.
23. Celsi, Richard and Jerry Olson (1988), "The Role of Involvement in Attention and Comprehension Processes," Journal of Consumer Research, 15 (2), 210-24.
24. Centers for Medicare & Medicaid Services, Office of the Actuary (2008), "National Health Expenditure Projections 2007-2017," (accessed October 20, 2008), [available at www.cms.hhs.gov/ NationalHealthExpendData/ Downloads/proj2007.pdfJ.
25. Chandran, Sucharita and Geeta Menon (2004), "When a Day Means More Than a Year: Effects of Temporal Framing on Judgments of Health Risk," Journal of Consumer Research, 31 (September), 375-89.
26. Chandy, Rajesh K., Brigitte Hopstaken, Om Narasimhan, and Jaideep Prabhu (2006), "From Invention to Innovation: Conversion Ability in Product Development," Journal of Marketing Research, 43 (August), 494-508.
27. Chintagunta, Pradeep K. and Ramarao Desiraju (2005), "Strategic Pricing and Detailing Behavior in International Markets," Marketing Science, 24 (1), 67-80.
28. Cleanthous, Paris (2004), "Informative Advertising in U.S. Pharmaceuticals," paper presented at the INFORMS 2004 Marketing Science Conference, Denver (June 24-27).
29. Cloodt, Myriam, John Hagedoorn, and Hans Van Kranenburg (2006), "Mergers and Acquisitions: Their Effect on the Innovative Performance of Companies in High-Tech Industries," Research Policy, 35 (5), 642-54.
30. Coleman, James S., Elihu Katz, and Herbert Menzel (1966), Medical Innovation: A Diffusion Study. Indianapolis: The BobbsMerill Company.
31. Danzón, Patricia M., Y. Richard Wang, and Liang Wang (2005), "The Impact of Price Regulation on the Launch Delay of New Drugs: Evidence from Twenty-Five Major Markets in the 1990s," Health Economics, 14 (3), 269-92.
32. Dekimpe, Marnik G. and Dominique M. Hanssens (1999), "Sustained Spending and Persistent Response: A New Look at Long-Term Marketing Profitability," Journal of Marketing Research, 36 (November), 397-412.
33. Dellande, Stephanie, Mary C. Gilly, and John L. Graham (2004), "Gaining Compliance and Losing Weight: The Role of the Service Provider in Health Care Services," Journal of Marketing, 68 (July), 78-91.
34. DeSarbo, Wayne S., Alexandru M. Degeratu, Michel Wedel, and M. Kim Saxton (2001), "The Spatial Representation of Market Information," Marketing Science, 20 (4), 426-41.
35. Desiraju, Ramarao, Harikesh Nair, and Pradeep K. Chintagunta (2004), "Diffusion of New Pharmaceutical Drugs in Developing and Developed Nations," International Journal of Research in Marketing, 21 (4), 341-57.
36. DiMasi, Joseph A., Ronald W. Hansen, and Henry G. Grabowski (2003), "The Price of Innovation: New Estimates of Drug Development Costs," Journal of Health Economics, 22 (2), 151-85.
37. Ding, Min and Jehoshua Eliashberg (2002), "Structuring the New Product Development Pipeline," Management Science, 48 (3), 343-63.
38. Dong, Xiaojing, Puneet Manchanda, and Pradeep K. Chintagunta (2008), "A Multi-Category Model of Physician Prescription and Detailing," Working Paper No. 09-10, Booth School of Business, University of Chicago.
39. Drummond, Michael, Bengt Jönsson, and Frans Rutten (1997), 'The Role of Economic Evaluation in the Pricing and Reimbursement of Medicines," Health Policy, 40 (3), 199-215.
40. Eliashberg, Jehoshua, Anita Elberse, and Mark A.A.M. Leenders (2006), "The Motion Picture Industry: Critical Issues in Practice, Current Research, and New Research Directions," Marketing Science, 25 (6), 638-61.
41. -and Steven M. Shugan (1997), "Film Critics: Influencers or Predictors?" Journal of Marketing, 61 (April), 68-78.
42. Ferguson, Jeffery M., Richard Discenza, and John A. Miller (1987), "Increasing the Odds of Patient Compliance Through Prescription Warning Labels," Journal of Health Care Marketing, 7 (1), 37-46.
43. Frank, Richard G. and David S. Salkever (1997), "Generic Entry and die Pricing of Pharmaceuticals," Journal of Economics and Management Strategy, 6 (1), 75-90.
44. Friedman, Margaret L. and Gilbert A. Churchill Jr. (1987), "Using Consumer Perceptions and a Contingency Approach to Improve Health Care Delivery," Journal of Consumer Research, 13 (4), 492-510.
45. Gallego, Gisselle, Susan J. Taylor, and Jo-anne E. Brien (2007), "Priority Setting for High Cost Medications (HCMs) in Public Hospitals in Australia: A Case Study," Health Policy, 84 (1), 58-66.
46. Garber, Alan M. and Charles E. Phelps (1997), "Economic Foundations of Cost-Effectiveness Analysis," Journal of Health Economics, 16 (1), 1-31.
47. Glazer, Rashi and Allen M. Weiss (1993), "Marketing in Turbulent Environments: Decision Processes and the Time-Sensitivity of Information," Journal of Marketing Research, 30 (November), 509-521.
48. Golder, Peter N. and Gerard J. Tellis (1993), "Pioneer Advantage: Marketing Logic or Marketing Legend?" Journal of Marketing Research, 30 (May), 158-70.
49. Gönül, Füsun F., Franklin Carter, Elina Petrova, and Kannan Srinivasan (2001), "Promotion of Prescription Drugs and Its Impact on Physicians' Choice Behavior," Journal of Marketing, 65 (July), 79-90.
50. Grabowski, Henry G. and John M. Vernon (1992), "Brand Loyalty, Entry, and Price-Competition in Pharmaceuticals After the 1984 Drug-Act," Journal of Law & Economics, 35 (2), 331-50.
51. Gregson, Nigel, Keiron Sparrowhawk, Josephine Mauskopf, and John Paul (2005), "Pricing Medicines: Theory and Practice, Challenges and Opportunities," Nature Reviews Drug Discovery, 4 (February), 121-30.
52. Gupta, Sachin, Yu Yu, and Rahul Guha (2006), "Pioneering Advantage in Generic Drug Competition," Johnson School Research Paper Series No. 37-06, Cornell University.
53. Hahn, Minhi, Sehoon Park, Lakshman Krishnamurthi, and Andris A. Zoltners (1994), "Analysis of New Product Diffusion Using a Four-Segment Trial-Repeat Model," Marketing Science, 13 (3), 224-47.
54. Heide, Jan B. and Allen M. Weiss (1995), "Vendor Consideration and Switching Behavior for Buyers in High-Technology Markets," Journal of Marketing, 59 (July), 30-43.
55. Hollis, Aidan (2002), "The Importance of Being First: Evidence From Canadian Generic Pharmaceuticals," Health Economics, 11 (8), 723-34.
56. Hong, Jiewen and Angela Y. Lee (2008), "Be Fit and Be Strong: Mastering Self-Regulation Through Regulatory Fit," Journal of Consumer Research, 34 (5), 682-95.
57. Hooper, Elizabeth M., Loretto M. Comstock, Jean M. Goodwin, and James S. Goodwin (1982), "Patient Characteristics That Influence Physician Behavior," Medical Care, 20 (6), 630-38.
58. Hopfield, Jessica, Robert M. Linden, and Bradley J. Tevelow (2006), "Getting Patients to Take Their Medicine," McKinsey Quarterly, 4 (November), 1-15.
59. Hunter, Derek (2005), "Guaranteed Future Pain and Suffering: The Recent Research on Drug Price Controls," WebMemo, 908, 1-3.
60. Iizuka, Toshiaki and Ginger Zhe Jin (2005), "The Effect of Prescription Drug Advertising on Doctor Visits," Journal of Economics and Management Strategy, 14 (3), 701-727.
61. Iyengar, Raghuram, Thomas W. Valente, and Christophe Van den Bulte (2008), "Opinion Leadership and Social Contagion in New Product Diffusion," working paper, Wharton School of Business, University of Pennsylvania.
62. John, George, Allen M. Weiss, and Shantanu Dutta (1999), "Marketing in Technology-Intensive Markets: Toward a Conceptual Framework," Journal of Marketing, 63 (Special Issue), 78-91.
63. Kahn, Barbara E., Eric Greenleaf, Julie R. Irwin, Alice M. Isen, Irwin P. Levin, Mary Frances Luce, et al. (1997), "Examining Medical Decision Making from a Marketing Perspective," Marketing Letters, 8 (3), 361-75.
64. -and Mary F. Luce (2003), "Understanding High-Stakes Consumer Decisions: Mammography Adherence Following False-Alarm Test Results," Marketing Science, 22 (3), 393-410.
65. - and- (2006), "Repeated-Adherence Protection Model: Tm OK, and It's a Hassle,'" Journal of Public Policy & Marketing, 25 (Spring), 79-89.
66. Kaplan, Sherrie H., Barbara Gandek, Sheldon Greenfield, William Rogers, and John E. Ware (1995), "Patient and Visit Characteristics Related to Physicians' Participatory Decision-Making Style," Medical Care, 33 (12), 1176-87.
67. Kappe, Eelco, Stefan Stremersch, and Sriram Venkataraman (2008), "Bucking the Trend in Pharmaceutical Detailing: Fusing Data to Gauge a Policy Shift," working paper, School of Economics, Erasmus University Rotterdam.
68. Keller, Punam A. (1999), "Converting the Unconverted: The Effect of Inclination and Opportunity to Discount Health-Related Fear Appeals," Journal of Applied Psychology, 84 (June), 403-415.
69. -(2006), "Regulatory Focus and Efficacy of Health Messages," Journal of Consumer Research, 33 (June), 109-114.
70. -and Lauren G. Block (1996), "Increasing the Persuasiveness of Fear Appeals: The Effect of Arousal and Elaboration," Journal of Consumer Research, 22 (4), 448-59.
71. - and- (1997), "Vividness Effects: A ResourceMatching Perspective," Journal of Consumer Research, 24 (3), 295-304.
72. -and Donald R. Lehmann (2008), "Designing Effective Health Communications: A Meta-Analysis," Journal of Public Policy & Marketing, 27 (Fall), 117-30.
73. -, Isaac M. Lipkus, and Barbara K. Rimer (2002), "Depressive Realism and Health Risk Accuracy: The Negative Consequences of Positive Mood," Journal of Consumer Research, 29 (1), 57-69.
74. -,-, and-(2003), "Affect, Framing, and Persuasion," Journal of Marketing Research, 40 (February), 54-64.
75. Kogut, B. and U. Zander (1992), "Knowledge of the Firm, Combinative Capabilities, and the Replication of Technology," Organization Science, 3 (3), 383-97.
76. Kremer, Sara T.M., Tammo H.A. Bijmolt, Peter S.H. Leeflang, and Jaap E. Wieringa (2008), "Generalizations on the Effectiveness of Pharmaceutical Promotional Expenditures," International Journal of Research in Marketing, 25 (4), 234-46.
77. Kyle, Margaret K. (2007), "Pharmaceutical Price Controls and Entry Strategies," Review of Economics and Statistics, 89 (1), 88-99.
78. Leeflang, Peter S.H., Jaap E. Wieringa, and Dick R. Wittink (2004), "The Effects of Pharmaceutical Marketing on Sales of Prescription Drugs in the Netherlands," working paper, Faculty of Economics and Business, University of Groningen.
79. Leffler, Keith B. (1981), "Persuasion or Information? The Economics of Prescription Drug Advertising," Journal of Law and Economics, 24 (1), 45-74.
80. Loch, Christoph H. and Stylianos Kavadias (2002), "Dynamic Portfolio Selection of NPD Programs Using Marginal Returns," Management Science, 48 (10), 1227-41.
81. López-Casasnovas, Guillem and Jaume Puig-Junoy (2000), "Review of the Literature on Reference Pricing," Health Policy, 54 (2), 87-123.
82. Luce, Mary F. and Barbara E. Kahn (1999), "Avoidance or Vigilance? The Psychology of False-Positive Test Results," Journal of Consumer Research, 26 (3), 242-59.
83. Macias, Wendy and Liza Stavchansky Lewis (2003), "A Content Analysis of Direct-to-Consumer (DTC) Prescription Drug Web Sites," Journal of Advertising, 32 (4), 43-56.
84. Maddux, James E. and Ronald W. Rogers (1983), "Protection Motivation and Self-Efficacy: A Revised Theory of Fear Appeals and Attitude Change," Journal of Experimental Social Psychology, 19 (5), 469-79.
85. Madhaven, Ravindranath and Rajiv Grover (1998), "From Embedded Knowledge to Embodied Knowledge: New Product Development as Knowledge Development," Journal of Marketing, 62 (October), 1-12.
86. Manchanda, Puneet and Pradeep K. Chintagunta (2004), "Responsiveness of Physician Prescription Behavior to Salesforce Effort: An Individual Level Analysis," Marketing Letters, 15 (2-3), 129-45.
87. -, Xiaojing Dong, and Pradeep K. Chintagunta (2004), "A Multicategory Model of Physician Prescription Behavior," working paper, Booth School of Business, University of Chicago.
88. -and Elisabeth Honka (2005), "The Effects and Role of Direct-to-Physician Marketing in the Pharmaceutical Industry: An Integrative Review," Yale Journal of Health Policy, Law and Ethics, 5 (2), 785-822.
89. -, Peter E. Rossi, and Pradeep K. Chintagunta (2004), "Response Modeling with Nonrandom Marketing-Mix Variables," Journal of Marketing Research, 41 (November), 467-78.
90. Mantrala, Murali K., Prabhakant Sinha, and Andris A. Zoltners (1994), "Structuring a Multiproduct Sales Quota-Bonus Plan for a Heterogeneous Sales Force: A Practical Model-Based Approach," Marketing Science, 13 (2), 121-44.
91. Menon, Geeta, Lauren G. Block, and Suresh Ramanathan (2002), "We're at as Much Risk as We Are Led to Believe: Effects of Message Cues on Judgments of Health Risk," Journal of Consumer Research, 28 (4), 533-49.
92. -, Priya Raghubir, and Nidhi Agrawal (2008), "Health Risk Perceptions and Consumer Psychology," in The Handbook of Consumer Psychology, Curtis Haugtvedt, Paul Herr, and Frank Kardes, eds. New York: Lawrence Erlbaum Associates, 981-1010.
93. Mizik, Natalie and Robert Jacobson (2004), "Are Physicians 'Easy Marks'? Quantifying the Effects of Detailing and Sampling on New Prescriptions," Management Science, 50 (12), 1704-1715.
94. Moorman, Christine (1990), "The Effects of Stimulus and Consumer Characteristics on the Utilization of Nutrition Information," Journal of Consumer Research, 17 (December), 362-74.
95. -(1998), "Market-Level Effects of Information: Competitive Responses and Consumer Dynamics," Journal of Marketing Research, 35 (February), 82-98.
96. -, Kristin Diehl, David Brinberg, and Blair Kidwell (2004), "Subjective Knowledge, Search Locations, and Consumer Choice," Journal of Consumer Research, 31 (3), 673-80.
97. -, Rex Du, and Carl F. Mela (2005), "The Effect of Standardized Information on Firm Survival and Marketing Strategies," Marketing Science, 24 (2), 263-74.
98. -and Erika Matulich (1993), "A Model of Consumers' Preventive Health Behaviors: The Role of Health Motivation and Health Ability," Journal of Consumer Research, 20 (September), 208-228.
99. - and Rebecca J. Slotegraaf (1999), "The Contingency Value of Complementary Capabilities in Product Development," Journal of Marketing Research, 36 (May), 239-57.
100. Mukherji, Prokriti, Shantanu Dutta, and Surendra Rajiv (2004), "Estimating the Effects of Direct-to-Consumer Advertising for Prescription Drugs: A Natural Experiment," paper presented at the INFORMS 2004 Marketing Science Conference, Denver (June 24-27).
101. Nair, Harikesh, Puneet Manchanda, and Tulikaa Bhatia (2006), "Asymmetric Peer Effects in Physician Prescription Behavior: The Role of Opinion Leaders," Research Paper No. 1970, Stanford Graduate School of Business, Stanford University.
102. Narayanan, Sridhar, Ramarao Desiraju, and Pradeep K. Chintagunta (2004), "Return on Investment Implications for Pharmaceutical Promotional Expenditures: The Role of MarketingMix Interactions," Journal of Marketing, 68 (October), 90-105.
103. -, Puneet Manchanda, and Pradeep K. Chintagunta (2005), 'Temporal Differences in the Role of Marketing Communication in New Product Categories," Journal of Marketing Research, 42 (August), 278-90.
104. Narin, Francis (2001), "Assessing Technological Competencies," in From Knowledge Management to Strategic Competence: Measuring Technological, Market and Organisational Innovation, Joe Tidd, ed. London: Imperial College Press, 155-95.
105. Oliver, Richard L. and Philip K. Berger (1979), "A Path Analysis of Preventive Health Care Decision Models," Journal of Consumer Research, 6 (2), 113-22.
106. Parasuraman, A., Valarie A. Zeithaml, and Leonard L. Berry (1985), "A Conceptual Model of Service Quality and Its Implications for Future Research," Journal of Marketing, 49 (Fall), 41-50.
107. Parsons, Leonard Jon and Piet Vanden Abeele (1981), "Analysis of Sales Call Effectiveness," Journal of Marketing Research, 18 (February), 107-113.
108. Pharmaceutical Research and Manufacturers of America (2008), Pharmaceutical Industry Profile 2008. Washington, DC: Pharmaceutical Research and Manufacturers of America.
109. Prabhu, Jaideep C., Rajesh K. Chandy, and Mark E. Ellis (2005), "The Impact of Acquisitions on Innovation: Poison Pill, Placebo, or Tonic?" Journal of Marketing, 69 (January), 114-30.
110. Quinn, James B., Jordan J. Baruch, and Karen Anne Zien (1997), Innovation Explosion. New York: The Free Press.
111. Raghubir, Pryia and Geeta Menon (1998), "AIDS and Me, Never the Twain Shall Meet: The Effects of Information Accessibility on Judgments of Risk and Advertising Effectiveness," Journal of Consumer Research, 25 (1), 52-63.
112. Rao, Raghunath Singh, Rajesh K. Chandy, and Jaideep C. Prabhu (2008), "The Fruits of Legitimacy: Why Some New Ventures Gain More from Innovation Than Others," Journal of Marketing, 72 (July), 58-75.
113. Riis, Jason, Joseph P. Simmons, and Geoffrey P. Goodwin (2008), "Preferences for Enhancement Pharmaceuticals: The Reluctance to Enhance Fundamental Traits," Journal of Consumer Research, 35 (October), 495-508.
114. Rogers, Ronald W. (1975), "A Protection Motivation Theory of Fear Appeals and Attitude Change," Journal of Psychology, 91 (1), 93-114.
115. Rosenstock, Irvin M. (1974), "Historical Origins of the Health Belief Model," Health Education Monographs, 2, 328-35.
116. -(1985), "Understanding and Enhancing Patient Compliance with Diabetic Regimens," Diabetes Care, 8 (6), 610-16.
117. Rust, Roland T. and Tuck Siong Chung (2006), "Marketing Models of Service and Relationships," Marketing Science, 25 (6), 560-80.
118. Scherer, Frederic M. (1993), "Pricing, Profits, and Technological Progress in the Pharmaceutical Industry," Journal of Economic Perspectives, 7 (3), 97-115.
119. - (2004), "The Pharmaceutical Industry: Prices and Progress," New England Journal of Medicine, 351 (9), 927-32.
120. Shankar, Venkatesh (1997), "Pioneers' Marketing Mix Reactions to Entry in Different Competitive Game Structures: Theoretical Analysis and Empirical Illustration," Marketing Science, 16 (3), 271-93.
121. -, Gregory S. Carpenter, and Lakshman Krishnamurthi (1998), "Late Mover Advantage: How Innovative Late Entrants Outsell Pioneers," Journal of Marketing Research, 35 (February), 54-70.
122. -,-, and-(1999), 'The Advantage of Entry in the Growth Stage of the Product Life Cycle: An Empirical Analysis," Journal of Marketing Research, 36 (May), 269-76.
123. Singh, Jagdip, Rama Jayanti, and Elizabeth Gannon (2008), "Strong Medicine: Conflict of Interests and Pharmaceutical Marketing Practices," working paper, Weatherhead School of Management, Case Western Reserve University.
124. Sorescu, Alina B., Rajesh K. Chandy, and Jaideep C. Prabhu (2003), "Sources and Financial Consequences of Radical Innovation: Insights from Pharmaceuticals," Journal of Marketing, 67 (October), 82-102.
125. -,-, and-(2007), "Why Some Acquisitions Do Better Than Odiers: Product Capital as a Driver of Long-Term Stock Returns," Journal of Marketing Research, 44 (February), 57-72.
126. Spangenberg, Eric R., David E. Sprott, Bianca Grohmann, and Ronn J. Smith (2003), "Mass-Communicated Prediction Requests: Practical Application and a Cognitive Dissonance Explanation for Self-Prophecy," Journal of Marketing, 67 (July), 47-62.
127. Stewart, David W. (2002), "Getting Published: Reflections of an Old Editor," Journal of Marketing, 66 (October), 1-6.
128. Stremersch, Stefan (2008), "Health and Marketing: The Emergence of a New Field of Research," International Journal of Research in Marketing, 25 (4), 229-33.
129. - and Aurélie Lemmens (2009), "Sales Growth of New Pharmaceuticals Across the Globe: The Role of Regulatory Regimes," Marketing Science, forthcoming.
130. -and Gerard J. Tellis (2002), "Strategic Bundling of Products and Prices: A New Synthesis for Marketing," Journal of Marketing, 66 (January), 55-72.
131. -,-, Philip Hans Franses, and Jeroen L.G. Binken (2007), "Indirect Network Effects in New Product Growth," Journal of Marketing, 71 (July), 52-74.
132. -and Peter C. Verhoef (2005), "Globalization of Authorship in the Marketing Discipline: Does It Help or Hinder the Field?" Marketing Science, 24 (4), 585-94.
133. -, Isabel Verniers, and Peter C. Verhoef (2007), "The Quest for Citations: Drivers of Article Impact," Journal of Marketing, 71 (July), 171-93.
134. Thompson, Craig J. (2004), "Marketplace Mythology and Discourses of Power," Journal of Consumer Research, 31 (1), 162-80.
135. -(2005), "Consumer Risk Perceptions in a Community of Reflexive Doubt," Journal of Consumer Research, 32 (2), 235-48.
136. -and Maura Troester (2002), "Consumer Value Systems in the Age of Postmodern Fragmentation: The Case of the Natural Health Microculture," Journal of Consumer Research, 28 (4), 550-71.
137. Uzzi, Brian (1997), "Social Structure and Competition in Interfirm Networks: The Paradox of Embeddedness," Administrative Science Quarterly, 42 (1), 35-67.
138. Van den Bulte, Christophe and Gary L. Lilien (2001), "Medical Innovation Revisited: Social Contagion Versus Marketing Effort," American Journal of Sociology, 106 (5), 1409-1435.
139. Vargo, Stephen L. and Robert F. Lusch (2004), "Evolving to a New Dominant Logic for Marketing," Journal of Marketing, 68 (January), 1-17.
140. Venkataraman, Sriram and Stefan Stremersch (2007), "The Debate on Influencing Doctors' Decisions: Are Drug Characteristics the Missing Link?" Management Science, 53 (11), 1688-1701.
141. Verbrugge, Lois M. (1985), "Gender and Health: An Update on Hypotheses and Evidence," Journal of Health and Social Behavior, 26 (September), 156-82.
142. Verniers, Isabel, Stefan Stremersch, and Christophe Croux (2008), "International Launch Timing and Pricing of New Pharmaceuticals," working paper, School of Economics, Erasmus University Rotterdam.
143. Vernon, John A. and W. Keener Hughen (2005), "The Future of Drug Development: The Economics of Pharmacogenomics," National Bureau of Economic Research Working Paper No. 11875.
144. Weiss, Allen M. and Jan B. Heide (1993), 'The Nature of Organizational Search in High Technology Markets," Journal of Marketing Research, 30 (May), 220-33.
145. Wong, Nancy and Tracey King (2008), 'The Cultural Construction of Risk Understandings Through Illness Narratives," Journal of Consumer Research, 34 (5), 579-94.
146. Wosinska, Marta (2005), "Direct-to-Consumer Advertising and Drug Therapy Compliance," Journal of Marketing Research, 42 (August), 323-32.
147. -(2006), "Direct-to-Consumer Advertising, Media Publicity and Demand for Prescription Drugs," paper presented at INFORMS 2006 Marketing Science Conference, University of Pittsburgh (June 8-10).
148. Wuyts, Stefan, Massimo G. Colombo, Shantanu Dutta, and Bart Nooteboom (2005), "Empirical Tests of Optimal Cognitive Distance," Journal of Economic Behavior and Organization, 58 (2), 277-302.
149. -, Shantanu Dutta, and Stefan Stremersch (2004), "Portfolios of Interfirm Agreements in Technology-Intensive Markets: Consequences for Innovation and Profitability," Journal of Marketing, 68 (April), 88-100.